%0 Journal Article
%T Still a hopeless case for personalized oncology? Pancreatic cancer revisited
%A Jens T. Siveke
%A Martin R. Sprick
%A Wilko Weichert
%J Archive of "Oncoscience".
%D 2019
%R 10.18632/oncoscience.464
%X In many cancer entities, morphomolecularly informed, individually tailored, targeted treatment has strongly improved patient outcome. Recent advances in immune oncology in concert with novel targeted molecular agents even brought pharmacological ¡°cure¡± within reach for a considerable number of patients with metastatic solid tumors. However, as always in the last decades, one of the large tumor entities is left behind: pancreatic cancer
%K pancreatic cancer
%K personalized oncology
%K ge-nomics
%K RNA subtypes
%K prognosis
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382256/